Page 5 - Read Online
P. 5
www.cdrjournal.com
Special Issue
Targeted cancer therapy
Guest Editors:
Special Issue Introduction
Dr. Elisa Giovannetti, Targeted therapies in cancer aim to specically block the activity of
MD, PhD crucial proteins or signaling pathways necessary for the growth and/or
Lab Medical Oncology, VU survival of tumor cells. A major breakthrough in targeted cancer
University Medical Center therapy was the introduction nearly two decades ago of imatinib, an
(Vumc), Cancer Center inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic
Amsterdam, the myeloid leukemia. Over the last years, signicant advances in our
Netherlands. understanding of tumor biology have facilitated the development of
Cancer Pharmacology Lab, many drugs targeting not only kinases, but also other protein families
AIRC Start-Up Unit, University and cellular processes. Several of these agents are currently employed
of Pisa, Italy. or being implemented for the treatment of different hematologic and
Email: solid malignancies, such as lung cancer.
elisa.giovannetti@gmail.com The special issue on “Targeted cancer therapy” will include Reviews
and Commentaries updating the clinical use of targeted agents in the
Dr. Jose Antonio treatment of different tumor types, and the mechanisms that underlie
the action of drugs directed to different types of targets. The special
Rodriguez, PhD
issue will also include Research articles presenting novel outstanding
Department of Genetics,
data on all aspects of targeted cancer therapy. All submissions will
Physical Anthropology and
undergo rigorous peer revision and will be published free of charge
Animal Physiology (School of
upon acceptance.
Medicine and Nursing) of
the University of the Basque
Benets
Country (UPV/EHU), Basque
Rigorous mechanism in peer review: one manuscript must be
Country, Spain.
reviewed by at least two relevant experts. We will endeavour to
Email:
ensure high standards for the review process and subsequent
josean.rodriguez@ehu.es
publication by a team of efcient and professional reviewers and
scientic editors.
No publication fee: there would be absolutely no charge for
publication.
Rapid publication: we will ensure that accepted papers will be
published in a short processing time (the average processing time:
50.7 days) with a high quality.
Open Access: As an author you will retain the copyright to your work.
By licensing your work under the Creative Commons Attribution
License, articles can be re-used and re-distributed without restriction,
as long as the original work is correctly cited.
Wide promotions: Published articles will be promoted at academic
conferences, through social networks for scientists and relevant
indexing services.
245 E Main Street ste122, Alhambra, CA 91801, USA；
www.cdrjournal.com/journal
Tel：+1 323 9987086；E-mail：editorial@cdrjournal.com /special_issues
